Disc Medicine Gets Orphan Drug Designation for Blood-Disorder Treatment

By Dean Seal

Disc Medicine said regulators have granted orphan drug designation for DISC-3405, its treatment for patients with the rare blood disorder polycythemia vera.

The clinical-stage biopharmaceutical company's chief executive, John Quisel, said Friday morning that the Food and Drug Administration's special status was an important milestone and that the company looks forward to sharing initial data from an ongoing Phase 1 trial of DISC-3405.

Orphan-drug designation is a special status given to drugs that show promise for potentially treating rare, or orphan, diseases that have fewer than 200,000 cases a year in the U.S.

Write to Dean Seal at [e-mail]

(END) Dow Jones Newswires

02-09-24 0923ET